article thumbnail

STAT+: Documents detail how pharmacy giants Walgreens, CVS, and Walmart failed patients in the opioid epidemic

STAT

In 2011, Walgreens executives were under pressure. Amid a growing addiction crisis, and with the country already awash in prescription painkillers, the federal government was demanding accountability from the pharmacy giant for filling thousands of opioid prescriptions written by doctors in suspiciously large quantities.  

article thumbnail

510(k) Modernization 2023

The FDA Law Blog

Lenz, Principal Medical Device Regulation Expert — On September 6, 2023, FDA announced its latest efforts to modernize the 510(k) process, outlining FDA’s latest improvements to strengthen the 510(k) Program and announcing release of three draft guidance documents.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis agrees $245m settlement over Exforge generics delay

pharmaphorum

The case revolves around allegations that Novartis made an agreement in 2011 with Par Pharmaceutical when Exforge (valsartan/amlodipine) was nearing the end of its patent life that was designed to keep Par’s generic version of the drug off the market until 30 September, 2014.

article thumbnail

How to qualify for a service animal

The Checkup by Singlecare

However, simply having a qualifying disability typically isn’t sufficient; the person also needs documentation from a medical professional that indicates that the service animal could improve or support his or her condition. Since March 15, 2011, only dogs a re officially recognized as service animals under titles II and III of the ADA.

article thumbnail

Red 40 side effects and how to avoid them

The Checkup by Singlecare

In 2011, the agency reported that it could not establish a relationship between color additives and hyperactivity in children in the general population. The FDA has denied any link between the two for years.

article thumbnail

Case Study 3 – Expert Regulatory Affairs Services for a European-Based Client

Impact Pharmaceutical Services

In 2011, following referral from another company, IMPACT (now part of Syner-G BioPharma Group) was contacted by a small development stage pharmaceutical company located in the United Kingdom to assist them with pre-IND activities for a new chemical entity for the treatment of asthma. Authored the client’s Pre-IND Briefing Document.

article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Having worked for CROs since graduating, Sophie joined Pfizer in 2011 and has had various roles within the UK and now global groups. She holds a Bachelor’s degree in Biological Sciences and a PhD in Molecular Biochemistry from the University of Reading, UK. He has participated in four interventional studies and nine others.